Angiogenesis inhibition: do tumours have a plan B?

Carmen Phillips

Hopes that angiogenesis inhibition could improve outcomes when used adjuvantly in colorectal cancer received a setback at the end of April, with the announcement that the NSABP C-08 trial had failed to meet its primary endpoint. Recent research into how tumours respond to these drugs may help explain the disappointing results.

Download full article

Be the first to comment

Leave a Reply

Your email address will not be published.